Quercetin pretreatment has been shown to act as a pro-oxidant in cisplatin-resistant ovarian adenocarcinoma cells, inducing ROS production by effectively reducing the levels of the Trx/TrxR antioxidant system (Trx1, Trx2, and TrxR1) and downregulating the mTOR/STAT3 pathways, which synergistically potentiate cisplatin cytotoxicity [165]. Here, TXN is linked to ovarian adenocarcinoma.